REQUEST A DEMO
Total
USD $0.00
Search more companies

Liopharm Sp. z o.o. (Poland)

Main Activities: All Other Food Manufacturing
Secondary Activities: Dog and Cat Food Manufacturing | Pharmaceutical and Medicine Manufacturing | Toilet Preparation Manufacturing | General Line Grocery Merchant Wholesalers | Pharmacies and Drug Stores | Department Stores | Other Miscellaneous Store Retailers | Outpatient Care Centers
Full name: Liopharm Sp. z o.o. Profile Updated: June 27, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Polish Download a sample report

Liopharm Sp. z o.o. is based in Poland, with the head office in Dabrowka. It operates in the All Other Food Manufacturing sector. It was first established on December 12, 2005. 11 - 50 (2024) employees currently work for Liopharm Sp. z o.o.. From the latest financial highlights, Liopharm Sp. z o.o. reported a net sales revenue increase of 40.36% in 2024. Its total assets decreased by 6.37% over the same period. In, 2024, the company’s net profit margin increased by 0.04%.

Headquarters
Ul. Polna 13/3
Dabrowka; Wielkopolskie; Postal Code: 62-070

Contact Details: Purchase the Liopharm Sp. z o.o. report to view the information.

Website: http://www.genactiv.pl

Basic Information
Total Employees:
Purchase the Liopharm Sp. z o.o. report to view the information.
Registered Capital:
Purchase the Liopharm Sp. z o.o. report to view the information.
Financial Auditors:
Purchase the Liopharm Sp. z o.o. report to view the information.
Incorporation Date:
December 12, 2005
Company Performance
Financial values in the chart are available after Liopharm Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
40.36%
Total Operating Revenue
37.46%
Operating Profit
50.08%
EBITDA
52.08%
Net Profit/Loss for the Period
40.69%
Total Assets
-6.37%
Total Equity
59.48%
Operating Profit Margin
1.53%
Net Profit Margin
0.04%
Return on Equity (ROE)
-4.98%
Debt / Equity
-91%
Quick Ratio
-0.03%
Cash Ratio
0.21%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?